Could this pill clear long COVID brain fog? new trial begins
NCT ID NCT06847191
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called bezisterim (NE3107) in 203 adults with long COVID who struggle with brain fog and fatigue. Participants take either the drug or a placebo twice daily for 84 days, and researchers measure changes in thinking, memory, and energy levels. The goal is to see if bezisterim can ease these lingering neurological symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bezisterim (NE3107)
What this could lead to
If it works, this could point toward a treatment for the brain fog and fatigue that plague many long COVID patients.
What could go wrong
This is an early Phase 2 proof-of-concept study, not a large definitive trial. The primary goal is to generate ideas, not prove success, so results may be unclear or not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centricity Research
Columbus, Georgia, 31904, United States
-
Chronicle Bio Inc.
Park City, Utah, 84119, United States
-
Clinical Trial Site
Jacksonville, Florida, 32258, United States
-
Clinical Trial Site
Farmington Hills, Michigan, 48334, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Illinois Research Network University of Illinois at Chicago
Chicago, Illinois, 60608, United States
-
Jadestone Clinical Research
Silver Spring, Maryland, 20904, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Norton Infectious Disease Institute
Louisville, Kentucky, 40202, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Swedish Center for Research and Innovation
Seattle, Washington, 98104, United States
-
UCSF
San Francisco, California, 94110, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Texas health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
West Virginia University
Morgantown, West Virginia, 26506, United States
-
Yale University
New Haven, Connecticut, 06519, United States
-
Zenos Clinical Research
Dallas, Texas, 75230, United States